Priyanka Grover
Stock Analyst at J.P. Morgan
(0.14)
# 4,730
Out of 5,088 analysts
30
Total ratings
24%
Success rate
-26.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Priyanka Grover
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Rated: Buy | $145 | $93.07 | +55.80% | 4 | Oct 15, 2026 | |
| RCUS Arcus Biosciences | Initiated Coverage: Buy | $41 | $18.61 | +120.31% | 1 | Oct 14, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $30 | $10.56 | +184.09% | 2 | Oct 13, 2026 | |
| NGNE Neurogene | Initiated Coverage: Buy | $60 | $28.82 | +108.19% | 1 | Oct 8, 2026 | |
| ELVN Enliven Therapeutics | Initiated Coverage: Buy | $75 | $45.08 | +66.37% | 1 | Oct 1, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Reiterated: Buy | n/a | $2.70 | - | 4 | Sep 15, 2026 | |
| MREO Mereo BioPharma Group | Reiterated: Sell | n/a | $0.3018 | - | 9 | Sep 15, 2026 | |
| NUVB Nuvation Bio | Reiterated: Buy | n/a | $4.77 | - | 2 | Sep 15, 2026 | |
| RXRX Recursion Pharmaceuticals | Reiterated: Buy | n/a | $4.24 | - | 3 | Sep 15, 2026 | |
| RLAY Relay Therapeutics | Reiterated: Buy | $31 | $19.47 | +59.22% | 3 | Aug 14, 2026 |
Rhythm Pharmaceuticals
Oct 15, 2026
Rated: Buy
Price Target: $145
Current: $93.07
Upside: +55.80%
Arcus Biosciences
Oct 14, 2026
Initiated Coverage: Buy
Price Target: $41
Current: $18.61
Upside: +120.31%
Kura Oncology
Oct 13, 2026
Reiterated: Buy
Price Target: $30
Current: $10.56
Upside: +184.09%
Neurogene
Oct 8, 2026
Initiated Coverage: Buy
Price Target: $60
Current: $28.82
Upside: +108.19%
Enliven Therapeutics
Oct 1, 2026
Initiated Coverage: Buy
Price Target: $75
Current: $45.08
Upside: +66.37%
BridgeBio Oncology Therapeutics
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.70
Upside: -
Mereo BioPharma Group
Sep 15, 2026
Reiterated: Sell
Price Target: n/a
Current: $0.3018
Upside: -
Nuvation Bio
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.77
Upside: -
Recursion Pharmaceuticals
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.24
Upside: -
Relay Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $31
Current: $19.47
Upside: +59.22%